Search

Your search keyword '"Zeder-Goess, Christine"' showing total 8 results
Start Over Author "Zeder-Goess, Christine"
8 results on '"Zeder-Goess, Christine"'

2. M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis

Author

Badmann, Susann, primary, Heublein, Sabine, additional, Mayr, Doris, additional, Reischer, Anna, additional, Liao, Yue, additional, Kolben, Thomas, additional, Beyer, Susanne, additional, Hester, Anna, additional, Zeder-Goess, Christine, additional, Burges, Alexander, additional, Mahner, Sven, additional, Jeschke, Udo, additional, Trillsch, Fabian, additional, and Czogalla, Bastian, additional

Published
2020
Full Text
View/download PDF

3. High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients

Author

Trebo, Anna, primary, Ditsch, Nina, additional, Kuhn, Christina, additional, Heidegger, Helene Hildegard, additional, Zeder-Goess, Christine, additional, Kolben, Thomas, additional, Czogalla, Bastian, additional, Schmoeckel, Elisa, additional, Mahner, Sven, additional, Jeschke, Udo, additional, and Hester, Anna, additional

Published
2020
Full Text
View/download PDF

4. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer

Author

Bick, Ulrich, Engel, Christoph, Krug, Barbara, Heindel, Walter, Fallenberg, Eva M., Rhiem, Kerstin, Maintz, David, Golatta, Michael, Speiser, Dorothee, Rjosk-Dendorfer, Dorothea, Laemmer-Skarke, Irina, Dietzel, Frederic, Schaefer, Karl Werner Fritz, Leinert, Elena, Weigel, Stefanie, Sauer, Stephanie, Pertschy, Stefanie, Hofmockel, Thomas, Hagert-Winkler, Anne, Kast, Karin, Quante, Anne, Meindl, Alfons, Kiechle, Marion, Loeffler, Markus, Schmutzler, Rita K., Blohmer, Jens-Uwe, Horn, Denise, Varon-Mateeva, Raymonda, Huebbel, Verena, Herold, Natalie, Puesken, Michael, Wimberger, Pauline, Meisel, Cornelia, Keller, Katja, Antoch, Gerald, Vesper, Anne-Sophie, Fehm, Tanja N., Schlegelberger, Brigitte, Auber, Bernd, Wallaschek, Hannah, Heil, Joerg, Schott, Sarah, Dikow, Nicola, Mundhenke, Christoph, Arnold, Norbert, Caliebe, Almuth, Briest, Susanne, Lemke, Johannes, Gril, Sabine, Pfeifer, Katharina, Ramser, Juliane, Mahner, Sven, Ditsch, Nina, Zeder-Goess, Christine, Tio, Joke, Burg, Matthias, Horvath, Judith, Siebert, Reiner, Bartholomae, Jasmin, Janni, Wolfgang, Bley, Thorsten, Woeckel, Achim, Haaf, Thomas, Zachariae, Silke, Bucksch, Karolin, Enders, Ute, Bick, Ulrich, Engel, Christoph, Krug, Barbara, Heindel, Walter, Fallenberg, Eva M., Rhiem, Kerstin, Maintz, David, Golatta, Michael, Speiser, Dorothee, Rjosk-Dendorfer, Dorothea, Laemmer-Skarke, Irina, Dietzel, Frederic, Schaefer, Karl Werner Fritz, Leinert, Elena, Weigel, Stefanie, Sauer, Stephanie, Pertschy, Stefanie, Hofmockel, Thomas, Hagert-Winkler, Anne, Kast, Karin, Quante, Anne, Meindl, Alfons, Kiechle, Marion, Loeffler, Markus, Schmutzler, Rita K., Blohmer, Jens-Uwe, Horn, Denise, Varon-Mateeva, Raymonda, Huebbel, Verena, Herold, Natalie, Puesken, Michael, Wimberger, Pauline, Meisel, Cornelia, Keller, Katja, Antoch, Gerald, Vesper, Anne-Sophie, Fehm, Tanja N., Schlegelberger, Brigitte, Auber, Bernd, Wallaschek, Hannah, Heil, Joerg, Schott, Sarah, Dikow, Nicola, Mundhenke, Christoph, Arnold, Norbert, Caliebe, Almuth, Briest, Susanne, Lemke, Johannes, Gril, Sabine, Pfeifer, Katharina, Ramser, Juliane, Mahner, Sven, Ditsch, Nina, Zeder-Goess, Christine, Tio, Joke, Burg, Matthias, Horvath, Judith, Siebert, Reiner, Bartholomae, Jasmin, Janni, Wolfgang, Bley, Thorsten, Woeckel, Achim, Haaf, Thomas, Zachariae, Silke, Bucksch, Karolin, and Enders, Ute

Abstract

Purpose To report on 10 years of high-risk service screening with annual MRI in the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A cohort of 4,573 high-risk, previously unaffected women (954 BRCA1 carriers, 598 BRCA2 carriers, 3021 BRCA1/2 non-carriers) participating in the GC-HBOC surveillance program was prospectively followed. Screening outcomes for 14,142 screening rounds with MRI between 2006 and 2015 were analyzed and stratified by risk group, type of screening round, and age. Results A total of 221 primary breast cancers (185 invasive, 36 in situ) were diagnosed within 12 months of an annual screening round with MRI. Of all cancers, 84.5% (174/206, 15 unknown) were stage 0 or I. In BRCA1 carriers, 16.9% (10/59, 5 unknown) of all incident cancers (screen-detected and interval cancers combined) and in BRCA2 carriers 12.5% (3/24, 4 unknown) were stage IIA or higher, compared to only 4.8% (2/42, 2 unknown) in high-risk BRCA1/2 non-carriers. Program sensitivity was 89.6% (95% CI 84.9-93.0) with no significant differences in sensitivity between risk groups or by age. Specificity was significantly lower in the first screening round (84.6%, 95% CI 83.6-85.7) than in subsequent screening rounds (91.1%, 95% CI 90.6-91.7), p < 0.001. Cancer detection rates (CDRs) and as a result positive predictive values were strongly dependent on type of screening round, risk group and patient age. CDRs ranged from 43.5 (95% CI 29.8-62.9) for the first screening round in BRCA2 carriers to 2.9 parts per thousand (95% CI 1.3-6.3) for subsequent screening rounds in high-risk non-carriers in the age group 30 to 39 years. Conclusions High-risk screening with MRI was successfully implemented in the GC-HBOC with high sensitivity and specificity. Risk prediction and inclusion criteria in high-risk non-carriers need to be adjusted to improve CDRs and thus screening efficacy in these patients.

Published
2019

5. Additional file 2: of EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Author

Semmlinger, Anna, Schoenfeldt, Viktoria Von, Wolf, Verena, Meuter, Alexandra, Kolben, Theresa, Kolben, Thomas, Zeder-Goess, Christine, Weis, Florian, Gallwas, Julia, Wuerstlein, Rachel, Hermelink, Kerstin, Schmoeckel, Elisa, Harbeck, Nadia, Mayr, Doris, Mahner, Sven, Jeschke, Udo, and Ditsch, Nina

Abstract

Figure S2. Schoenfeld residuals for EP3. To test for PH assumption, Schoenfeld residual test was performed for EP3 for OS and PFS. Schoenfeld residuals for EP3 are displayed (left: OS, right: PFS). There is no violation of PH assumption, as the ratio of both curves is stable over the time. (PDF 20 kb)

Published
2018
Full Text
View/download PDF

6. Additional file 1: of EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Author

Semmlinger, Anna, Schoenfeldt, Viktoria Von, Wolf, Verena, Meuter, Alexandra, Kolben, Theresa, Kolben, Thomas, Zeder-Goess, Christine, Weis, Florian, Gallwas, Julia, Wuerstlein, Rachel, Hermelink, Kerstin, Schmoeckel, Elisa, Harbeck, Nadia, Mayr, Doris, Mahner, Sven, Jeschke, Udo, and Ditsch, Nina

Abstract

Figure S1. Metastasis and local recurrence in sporadic breast cancer. 10-years Kaplan-Meier-estimates of cumulative metastasis (A) and cumulative local recurrence (B) of EP3 positive and negative patient groups are displayed. Estimated metastasis and local recurrence rates are displayed at the end of each graph, p-values in the upper left corner. EP3 positivity was significantly associated with reduced metastasis (A) and local recurrence (B). Note that in the rates of metastasis and local recurrence named there, all cases of metastasis/local recurrence are considered, regardless if they were the primary cause of progression or happened later in the course of disease; therefore, the sum of both rates here is higher than the progression rate named in Fig. 2. yrs.â =â years. (PDF 437 kb)

Published
2018
Full Text
View/download PDF

7. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Author

Rhiem, Kerstin, Auber, Bernd, Briest, Susanne, Dikow, Nicola, Ditsch, Nina, Dragicevic, Neda, Grill, Sabine, Hahnen, Eric, Horvath, Judit, Jaeger, Bernadette, Kast, Karin, Kiechle, Marion, Leinert, Elena, Morlot, Susanne, Puesken, Michael, Schaefer, Dieter, Schott, Sarah, Schroeder, Christopher, Siebers-Renelt, Ulrike, Solbach, Christine, Weber-Lassalle, Nana, Witzel, Isabell, Zeder-Goess, Christine, Schmutzler, Rita K., Rhiem, Kerstin, Auber, Bernd, Briest, Susanne, Dikow, Nicola, Ditsch, Nina, Dragicevic, Neda, Grill, Sabine, Hahnen, Eric, Horvath, Judit, Jaeger, Bernadette, Kast, Karin, Kiechle, Marion, Leinert, Elena, Morlot, Susanne, Puesken, Michael, Schaefer, Dieter, Schott, Sarah, Schroeder, Christopher, Siebers-Renelt, Ulrike, Solbach, Christine, Weber-Lassalle, Nana, Witzel, Isabell, Zeder-Goess, Christine, and Schmutzler, Rita K.

Abstract

Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk (R)) for the analysis of risk genes for familial breast and ovarian cancer. Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process. Key Messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.

8. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Author

Rhiem, Kerstin, Auber, Bernd, Briest, Susanne, Dikow, Nicola, Ditsch, Nina, Dragicevic, Neda, Grill, Sabine, Hahnen, Eric, Horvath, Judit, Jaeger, Bernadette, Kast, Karin, Kiechle, Marion, Leinert, Elena, Morlot, Susanne, Puesken, Michael, Schaefer, Dieter, Schott, Sarah, Schroeder, Christopher, Siebers-Renelt, Ulrike, Solbach, Christine, Weber-Lassalle, Nana, Witzel, Isabell, Zeder-Goess, Christine, Schmutzler, Rita K., Rhiem, Kerstin, Auber, Bernd, Briest, Susanne, Dikow, Nicola, Ditsch, Nina, Dragicevic, Neda, Grill, Sabine, Hahnen, Eric, Horvath, Judit, Jaeger, Bernadette, Kast, Karin, Kiechle, Marion, Leinert, Elena, Morlot, Susanne, Puesken, Michael, Schaefer, Dieter, Schott, Sarah, Schroeder, Christopher, Siebers-Renelt, Ulrike, Solbach, Christine, Weber-Lassalle, Nana, Witzel, Isabell, Zeder-Goess, Christine, and Schmutzler, Rita K.

Abstract

Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk (R)) for the analysis of risk genes for familial breast and ovarian cancer. Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process. Key Messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.

Catalog

Books, media, physical & digital resources
See catalog results